$2.685
-0.044 (-1.65%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de APUS por análisis de gráficos similares
Alphio's APUS stock price prediction model matches the current Apimeds Pharmaceuticals US Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.71 (+1.09%). The 1-week path is $2.73 (+1.57%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de Apimeds Pharmaceuticals US Inc?
Apimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
APUS cerró en $2.68 el Friday, tras bajar -1.65%
Apimeds Pharmaceuticals US Inc (APUS) last closed at $2.6849999, losing -1.65%. These facts feed the 1-day and 1-week APUS price prediction above.
Factores de la previsión
Los factores de la previsión de Apimeds Pharmaceuticals US Inc (APUS) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bearish
Seasonality
Bullish
SMA 20
Bearish
SMA 200
Bearish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de APUS, ordenadas por similitud.
Análisis de estacionalidad de APUS
Historically the probability of a positive November return for APUS is 66.67%. April offers the highest probability of a positive month at 100.00%, while June is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Proyecciones de precio a 10 años de APUS
| Mes | Precio mínimo | Precio medio | Precio máximo | ROI potencial |
|---|---|---|---|---|
| Nov 2026 | $1.80 | $2.14 | $2.61 | -20.40% |
| Dec 2026 | $1.92 | $1.96 | $2.05 | -26.94% |
En 2026, se proyecta que Apimeds Pharmaceuticals US Inc (APUS) oscile entre $1.80 y $2.61.
Previsión mensual de Apimeds Pharmaceuticals US Inc para 2026
En Nov de 2026, se proyecta que Apimeds Pharmaceuticals US Inc promedie $2.14, con un mínimo de $1.80 y un máximo de $2.61.
En Dec de 2026, se proyecta que Apimeds Pharmaceuticals US Inc promedie $1.96, con un mínimo de $1.92 y un máximo de $2.05.
Artículos relacionados
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.